Finance
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
🤖 AI
AI Summary & AI Analysis
⟳ AI is analyzing this article…
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.